High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients.
暂无分享,去创建一个
S. Anker | M. Cicoira | C. Davos | A. Coats | W. Doehner | A. Coats | A. Bolger | M. Rauchhaus | R. Sharma | Rakesh Sharma | F. Al-Nasser | C. Davos
[1] P. Robbins,et al. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. , 2000, Circulation.
[2] D. Wagner,et al. The role of tumor necrosis factor in the pathophysiology of heart failure. , 2000, Journal of the American College of Cardiology.
[3] R. Ferrari,et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. , 1999, Circulation.
[4] B. Bozkurt,et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. , 1999, Circulation.
[5] B. Bozkurt,et al. An overview of tumor necrosis factor α and the failing human heart , 1999 .
[6] P. Ponikowski,et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. , 1999, European heart journal.
[7] G. Schuler,et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. , 1999, Journal of the American College of Cardiology.
[8] F. Clubb,et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.
[9] P. Poole‐Wilson,et al. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. , 1998, QJM : monthly journal of the Association of Physicians.
[10] S. Anker,et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. , 1997, Journal of the American College of Cardiology.
[11] P. Ponikowski,et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.
[12] P. Ponikowski,et al. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. , 1997, Journal of the American College of Cardiology.
[13] P. Poole‐Wilson,et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. , 1997, The American journal of cardiology.
[14] P. Poole‐Wilson,et al. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. , 1997, European heart journal.
[15] D. Zechner,et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. , 1996, The Journal of clinical investigation.
[16] H. Oral,et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.
[17] M. Piepoli,et al. Predictors of exercise capacity in chronic heart failure. , 1994, European heart journal.
[18] M. Yoshizumi,et al. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. , 1993, Circulation research.
[19] Simon C Watkins,et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.
[20] R. Lenkinski,et al. Contribution of Skeletal Muscle Atrophy to Exercise Intolerance and Altered Muscle Metabolism in Heart Failure , 1992, Circulation.
[21] J. McMurray,et al. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. , 1991, British heart journal.
[22] F. Tristani,et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.
[23] H. Fillit,et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.
[24] D. Hossfeld,et al. TNF-induced cardiomyopathy , 1990, The Lancet.
[25] M. Singer,et al. TUMOUR NECROSIS FACTOR IN BRONCHOPULMONARY SECRETIONS OF PATIENTS WITH ADULT RESPIRATORY DISTRESS SYNDROME , 1989, The Lancet.
[26] J. Kovacs,et al. The cardiovascular response of normal humans to the administration of endotoxin. , 1989, The New England journal of medicine.
[27] K. Tracey,et al. Peptide Regulatory Factors CACHECTIN/TUMOUR NECROSIS FACTOR , 1989, The Lancet.
[28] K. Tracey,et al. Cachectin/tumour necrosis factor. , 1989, Lancet.
[29] J. Gabrilove,et al. The acute metabolic effects of tumor necrosis factor administration in humans. , 1987, Archives of surgery.
[30] R. H. T. Edwards,et al. Size and composition of the calf and quadriceps muscles in Duchenne muscular dystrophy A tomographic and histochemical study , 1983, Journal of the Neurological Sciences.
[31] M. Morrell,et al. ABSORPTION OF PENTAGASTRIN FROM GASTROINTESTINAL TRACT IN MAN , 1975, The Lancet.
[32] V. Schuermans,et al. IMPAIRED NEUTROPHIL PHAGOCYTOSIS , 1974 .